Integral Molecular, a biotechnology company, has announced the issuance of a new patent and patent family by the United States Patent and Trademark Office (USPTO) covering the composition of matter for its Lipoparticle technology. This ...
Tags: Lipoparticle Technology, USPTO
US-based drug discovery and development firm, Heptares Therapeutics has delivered the first stabilised G protein-coupled receptor (GPCR) called 'StaR' to MorphoSys for antibody discovery as part of their antibody therapeutics alliance. ...
Tags: Heptares Therapeutics, drug
arGEN-X, a clinical stage human monoclonal antibody therapeutics company, cin its SIMPLE Antibody research program collaboration with Shire Pharmaceuticals' Human Genetic Therapies division. The milestone, which was the first ...
MorphoSys and Heptares Therapeutics have signed a research deal to develop antibody therapeutics against G protein-coupled receptors (GPCRs). According to the deal, Heptares will produce stabilized receptors (StaRs) for MorphoSys proposed ...
Tags: antibody therapeutics, Heptares Therapeutics, GPCR disease
Amorfix Life Sciences and CNJ Holdings have signed an agreement to identify and develop therapeutic antibodies targeting disease specific epitopes (DSEs). The collaboration will make use of Amorfix's ProMIS discovery technology and the ...
Tags: Amorfix Life Sciences, CNJ Holdings, agreement, disease specific epitopes
AbD Serotec, MorphoSys' division for research and diagnostic antibodies, is set to introduce a series of the human combinatorial antibody library (HuCAL) anti-drug antibodies supporting the development of novel antibody therapeutics. The ...
Tags: AbD Serotec, HuCAL Anti-Drug Antibodies, antibody therapeutics, MorphoSys
Genmab and GlaxoSmithKline (GSK) have announced the submission of a new drug application (NDA) for Arzerra (ofatumumab) to the Japanese Ministry of Health, Labor and Welfare (MHLW). Arzerra (ofatumumab) is submitted for the approval ...
Tags: new drug application, Arzerra, chronic lymphocytic leukemia